Skip to main content

Table 4 Association of PD-L1 staining with clinicopathologic factors in triple-negative patients with neoadjuvant chemotherapy

From: Comparison of three scoring methods using the FDA-approved 22C3 immunohistochemistry assay to evaluate PD-L1 expression in breast cancer and their association with clinicopathologic factors

 TCTCICICsTIL level
FactorsNegativePositiveFisherNegativePositiveFisherNegativePositiveFisherLowHighFisher
N (%)N (%)P valueN (%)N (%)P valueN (%)N (%)P valueN (%)N (%)P value
Age[N = 37] [N = 34] [N = 34] [N = 37] 
 < 50 years14 (93)1 (7)0.055712 (80)3 (20)0.017113 (87)2 (13)0.06410 (63)6 (38)0.5085
 ≥ 50 years14 (64)8 (36) 7 (37)12 (63) 10 (53)9 (47) 10 (48)11 (52) 
Race/ethnicity[N = 37] [N = 34] [N = 34] [N = 37] 
 Black2 (40)3 (60)0.11762 (40)3 (60)0.63823 (60)2 (40)0.49171 (25)3 (75)0.6123
 White+Latino23 (82)5 (18) 14 (56)11 (44) 16 (64)9 (36) 17 (59)12 (41) 
 Others3 (75)1 (25) 3 (75)1 (25) 4 (100)0 (0) 2 (50)2 (50) 
Histologic type[N = 37] [N = 34] [N = 34] [N = 37] 
 IDC26 (79)7 (21)0.243617 (57)13 (43)120 (67)10 (33)117 (52)16 (48)0.6088
 Metaplastic2 (50)2 (50) 2 (50)2 (50) 3 (75)1 (25) 3 (75)1 (25) 
Histologic gradea[N = 37] [N = 34] [N = 34] [N = 37] 
 21 (100)0 (0)11 (100)0 (0)11 (100)0 (0)12 (67)1 (33)1
 327 (75)9 (25) 18 (55)15 (45) 22 (67)11 (33) 18 (53)16 (47) 
sTIL level[N = 35] [N = 32] [N = 32] NA  
 < 10%16 (84)3 (16)0.245311 (61)7 (39)0.476512 (67)6 (33)1   
 ≥ 10%10 (63)6 (38) 6 (43)8 (57) 9 (64)5 (36)    
Tumor size[N = 37] [N = 34] [N = 34] [N = 37] 
 ≤ 2 cm9 (69)4 (31)0.7966 (60)4 (40)0.82877 (70)3 (30)16 (43)8 (57)0.158
 > 2 to 5 cm8 (80)2 (20) 6 (60)4 (40) 7 (70)3 (30) 3 (38)5 (63) 
 > 5 cm11 (79)3 (21) 7 (50)7 (50) 9 (64)5 (36) 11 (73)4 (27) 
ypN[N = 37] [N = 34] [N = 34] [N = 37] 
 (y)pN014 (74)5 (26)0.543511 (65)6 (35)0.411413 (76)4 (24)0.636511 (61)7 (39)0.1457
 (y)pN16 (86)1 (14) 4 (67)2 (33) 4 (67)2 (33) 2 (25)6 (75) 
 (y)pN24 (57)3 (43) 2 (29)5 (71) 4 (57)3 (43) 4 (50)4 (50) 
 (y)pN34 (100)0 (0) 2 (50)2 (50) 2 (50)2 (50) 3 (100)0 (0) 
pM[N = 37] [N = 34] [N = 34] [N = 37] 
 025 (74)9 (26)0.562218 (58)13 (42)0.571422 (71)9 (29)0.23917 (50)17 (50)0.2342
 13 (100)0 (0) 1 (33)2 (67) 1 (33)2 (67) 3 (100)0 (0) 
RCB category[N = 37] [N = 34] [N = 34] [N = 37] 
 I1 (50)1 (50)0.45780 (0)1 (100)0.0590 (0)1 (100)0.08241 (50)1 (50)0.8668
 II16 (80)4 (20) 13 (72)5 (28) 15 (83)3 (17) 12 (57)9 (43) 
 III11 (73)4 (27) 6 (40)9 (60) 8 (53)7 (47) 7 (50)7 (50) 
  1. aHistologic grade for post-treatment tumors was based on pre-treatment grade
  2. IDC invasive ductal carcinoma, sTIL stromal tumor infiltrating lymphocytes, RCB residual cancer burden